NASDAQ : CRVO
CervoMed Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 1.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 26.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
CervoMed Inc. (CRVO) reported revenue of 331.30K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Revenue | 331.30K | 4.01M | 9.74M | 7.14M | ||
| Cost of Revenue | 21.33M | 21.82M | 18.80M | 8.44M | 1.34M | |
| Gross Profit | -21.00M | -17.81M | -9.06M | -1.29M | -1.34M | |
| Selling, General & Admin | 10.17M | 10.48M | 9.17M | 6.52M | 2.14M | 2.62M |
| Research & Development | 2.42M | |||||
| Operating Expenses | 10.17M | 10.48M | 9.17M | 6.52M | 2.14M | 5.04M |
| Operating Income | -31.16M | -28.29M | -18.23M | -7.81M | -3.48M | -5.04M |
| Interest Expense | -587.00 | -429.00 | ||||
| Interest & Investment Income | 812.01K | 1.34M | 1.94M | 219.43K | 62.23K | 19.85K |
| Other Non Operating Income (Expenses) | 3.04K | -8.33K | -991.00 | 5.42M | -2.39M | 735.00K |
| EBT Excluding Unusual Items | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -4.28M |
| Other Unusual Items | 147.25K | |||||
| Pretax Income | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -4.14M |
| Net Income | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -4.14M |
| Net Income to Common | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -4.14M |
| Shares Outstanding (Basic) | 9.51M | 9.04M | 8.07M | 2.66M | 518.14K | 4.50M |
| Shares Outstanding (Diluted) | 9.51M | 9.04M | 8.07M | 2.66M | 518.14K | 4.50M |
| EPS (Basic) | -3.19 | -2.98 | -2.02 | -0.82 | -11.20 | -0.92 |
| EPS (Diluted) | -3.19 | -2.98 | -2.02 | -0.82 | -11.20 | -0.92 |
| Gross Margin | -93.04% | -18.11% | ||||
| Operating Margin | -9,406.96% | -706.22% | -187.18% | -109.35% | ||
| Profit Margin | -9,160.94% | -673.06% | -167.29% | -30.40% | ||
| EBIT | -31.16M | -28.29M | -18.23M | -7.81M | -3.48M | -5.04M |
| EBIT Margin | -187.18% | -109.35% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 22.46M | 8.24M | 9.00M | 7.79M | 4.09M | 6.67M |
| Short-Term Investments | 2.48M | 12.63M | 29.92M | |||
| Cash & Short-Term Investments | 24.94M | 20.86M | 38.92M | 7.79M | 4.09M | 6.67M |
| Accounts Receivable | 426.99K | 2.25M | 915.40K | |||
| Other Receivables | 69.58K | |||||
| Receivables | 426.99K | 2.25M | 915.40K | 69.58K | ||
| Prepaid Expenses | 733.72K | 1.27M | 1.91M | 1.26M | 64.13K | 24.71K |
| Other Current Assets | 320.58K | 320.58K | 54.94K | |||
| Total Current Assets | 25.99M | 22.88M | 43.08M | 9.96M | 4.16M | 6.82M |
| Other Long-Term Assets | 7.77K | |||||
| Total Assets | 25.99M | 22.88M | 43.08M | 9.97M | 4.16M | 6.82M |
| Accounts Payable | 687.11K | 1.45M | 1.51M | 662.47K | 97.30K | 18.15K |
| Accrued Expenses | 2.29M | 3.12M | 2.25M | 1.84M | 593.93K | 396.67K |
| Current Portion of Long-Term Debt | 12.41M | 4.11M | ||||
| Other Current Liabilities | 54.04K | 83.38K | 115.88K | 88.66K | 50.32K | 31.90K |
| Total Current Liabilities | 3.03M | 4.66M | 3.88M | 2.60M | 13.16M | 4.56M |
| Long-Term Debt | 5.92M | |||||
| Total Liabilities | 3.03M | 4.66M | 3.88M | 2.60M | 13.16M | 10.47M |
| Common Stock | 13.53K | 9.25K | 8.70K | 5.67K | 518.00 | 4.50K |
| Additional Paid-In Capital | 135.18M | 115.91M | 109.87M | 61.81M | 18.98M | 18.52M |
| Retained Earnings | -112.23M | -97.70M | -70.73M | -54.44M | -52.27M | -46.47M |
| Comprehensive Income & Other | 106.00 | 5.82K | 56.20K | |||
| Total Common Equity | 22.96M | 18.22M | 39.20M | 7.38M | -33.29M | -27.94M |
| Shareholders' Equity | 22.96M | 18.22M | 39.20M | 7.38M | -9.00M | -3.66M |
| Total Liabilities & Equity | 25.99M | 22.88M | 43.08M | 9.97M | 4.16M | 6.82M |
| Total Debt | 12.41M | 10.03M | ||||
| Net Cash (Debt) | 24.94M | 20.86M | 38.92M | 7.79M | -8.32M | -3.36M |
| Net Cash Per Share | 2.62 | 2.31 | 4.82 | 2.93 | -16.06 | -0.75 |
| Filing Date Shares Outstanding | 15.12M | 9.26M | 8.70M | 6.17M | 4.50M | 4.50M |
| Total Common Shares Outstanding | 13.53M | 9.25M | 8.70M | 5.67M | 4.50M | 4.50M |
| Working Capital | 22.96M | 18.22M | 39.20M | 7.37M | -9.00M | 2.26M |
| Book Value Per Share | 1.70 | 1.97 | 4.50 | 1.30 | -7.39 | -6.21 |
| Tangible Book Value | 22.96M | 18.22M | 39.20M | 7.38M | -33.29M | -27.94M |
| Tangible Book Value Per Share | 1.70 | 1.97 | 4.50 | 1.30 | -7.39 | -6.21 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -4.14M |
| Loss (Gain) From Sale of Investments | -456.83K | -854.08K | -1.21M | |||
| Stock-Based Compensation | 1.30M | 1.45M | 1.41M | 407.63K | 461.35K | 958.10K |
| Other Operating Activities | -5.42M | 2.39M | -901.73K | |||
| Change in Accounts Payable | -1.11M | -67.32K | 848.97K | 565.17K | 79.15K | -150.68K |
| Change in Other Net Operating Assets | 2.63M | 2.99M | -1.29M | -826.52K | 300.78K | 95.22K |
| Operating Cash Flow | -27.98M | -23.45M | -16.53M | -7.45M | -2.57M | -4.13M |
| Investment in Securities | 23.19M | 18.10M | -28.66M | |||
| Investing Cash Flow | 23.19M | 18.10M | -28.66M | |||
| Long-Term Debt Issued | 6.00M | |||||
| Net Debt Issued (Repaid) | 6.00M | |||||
| Issuance of Common Stock | 18.93M | 4.59M | 46.40M | 810.00K | ||
| Other Financing Activities | 10.34M | |||||
| Financing Cash Flow | 18.93M | 4.59M | 46.40M | 11.15M | 6.00M | |
| Net Cash Flow | 14.14M | -764.03K | 1.21M | 3.70M | -2.57M | 1.87M |
| Levered Free Cash Flow | -16.29M | -13.31M | -10.69M | -4.73M | -1.33M | |
| Unlevered Free Cash Flow | -16.29M | -13.31M | -10.69M | -4.73M | -1.33M | |
| Change in Working Capital | 1.53M | 2.92M | -440.66K | -261.36K | 379.94K | -55.46K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 24.49M | 73.10M | 19.31M | 43.30M | ||
| Enterprise Value | -445.24K | 45.80M | -27.34M | 32.87M | ||
| Last Close Price | 1.60 | 7.90 | 2.34 | 7.63 | ||
| PS Ratio | 73.02 | 18.24 | 1.98 | 6.06 | ||
| PB Ratio | 0.94 | 4.01 | 0.49 | 5.87 | ||
| P/TBV Ratio | 1.05 | 4.01 | 0.49 | 5.87 | ||
| EV/Sales Ratio | 11.43 | 4.60 | ||||
| Debt / Equity Ratio | -1.38 | -2.74 | ||||
| Net Debt / Equity Ratio | -1.09 | -1.15 | -0.99 | -1.06 | -0.93 | -0.92 |
| Asset Turnover | 0.01 | 0.12 | 0.37 | 1.01 | ||
| Quick Ratio | 8.22 | 4.57 | 10.61 | 3.35 | 0.31 | 1.48 |
| Current Ratio | 8.57 | 4.91 | 11.11 | 3.84 | 0.32 | 1.50 |
| Return on Equity (ROE) | -107.62% | -93.92% | -69.95% | |||
| Return on Assets (ROA) | -60.80% | -53.62% | -42.95% | -69.12% | -39.59% | |
| Return on Capital Employed (ROCE) | -135.70% | -155.30% | -46.50% | -105.90% | 38.60% | -223.00% |
| Earnings Yield | -197.10% | -36.89% | -84.35% | -5.02% | ||
| Buyback Yield / Dilution | -8.40% | -12.00% | -203.34% | -413.65% | 88.49% |